Bradmer Announces Fourth Quarter and Full Year 2016 Financial Results

TORONTO, ONTARIO--(Marketwired - April 18, 2017) - Bradmer Pharmaceuticals Inc. (NEX:BMR.H) ("Bradmer" or the "Company") today announced its fourth quarter and full year 2016 financial results.

Financial Results

Amounts in US dollars, unless specified otherwise, and results prepared in accordance with International Financial Reporting Standards ("IFRS").

For the three months ended December 31, 2016, the Company recorded a net loss of $21,000 or $0.001 per common share based on the weighted average outstanding shares of 19,659,726 during the three month period, compared to a net loss of $7,000 or $0.000 per common share for the quarter ended December 31, 2015 based on the weighted average outstanding shares of 19,659,726.

General and administrative expenses were $31,000 in the three months ended December 31, 2016 compared to $22,000 in the same quarter of the prior year. Major expenses in 2016 consisted of consulting fees of $13,000, directors' and officers' liability insurance premiums of $2,000, audit fees of $2,000 and legal fees of $8,000. In 2015 major expenses consisted of consulting fees of $13,000, directors' and officers' liability insurance premiums of $3,000, audit fees of $2,000 and legal fees of $1,000.

The $10,000 foreign exchange gain in the fourth quarter of 2016 compared with a $15,000 foreign exchange gain in the same quarter of 2015.

For the year ended December 31, 2016, the Company recorded a net loss of $136,000 or $0.007 per common share based on the weighted average outstanding shares of 19,659,726 during the period, compared to a net loss of $60,000 or $0.003 per common share for the year ended December 31, 2015 based on the weighted average outstanding shares of 19,659,726.

General and administrative expenses were $123,000 in the year ended December 31, 2016 compared to $131,000 in the prior year. Major expenses in 2016 consisted of consulting fees of $54,000, legal fees of $32,000, insurance premiums of $10,000, audit fees of $10,000 and transfer agent and stock exchange listing fees of $12,000. Major expenses in 2015 consisted of a work fee from WCM Capital of $19,500, consulting fees of $56,000, legal fees of $21,000, insurance premiums of $11,000, audit fees of $10,000 and transfer agent and stock exchange listing fees of $8,000.

The main reason for the increased net loss in 2016 is due to the $12,000 foreign exchange loss compared with a $71,000 foreign exchange gain in 2015.

Bradmer's operational activities for the year ended December 31, 2016 were financed by cash on hand. At December 31, 2016, the Company had working capital of $382,000, compared to $500,000 at December 31, 2015. Bradmer had available cash of $414,000 (CDN $556,000) as at December 31, 2016, compared to cash of $521,000 (CDN $721,000) as at December 31, 2015. The $107,000 decrease in cash was due to the $135,000 net loss offset by $17,000 of foreign exchange adjustments and the $11,000 decrease in non-cash working capital.

As at April 18, 2017 and December 31, 2016, the Company had 19,659,726 common shares and options to purchase 1,950,000 common shares outstanding.

Bradmer Pharmaceuticals Inc.

Paul Van Damme
Chief Financial Officer

Additional information about Bradmer, including the MD&A and financial results may be found on SEDAR at www.sedar.com.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Bradmer's common shares have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.

Except for historical information, this news release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

BRADMER PHARMACEUTICALS INC.
Statements of Financial Position
As at December 31
(All amounts expressed in United States dollars)

			2016		2015
Assets
Current assets
	Cash	$	413,894	$	520,758
	Amounts receivable		3,413		5,098
	Prepaid expenses		1,176		1,268
Total assets		$	418,483	$	527,124
Liabilities and Shareholders' Equity
Current liabilities
	Accounts payable and accrued liabilities	$	36,759	$	27,039
Shareholders' Equity
	Share capital		1,710,138		1,659,105
	Contributed surplus		1,889,755		1,833,363
	Accumulated other comprehensive income		895,332		985,568
	Deficit		(4,113,501)		(3,977,951)
Total shareholders' equity			381,724		500,085
Total liabilities and shareholders' equity		$	418,483	$	527,124

BRADMER PHARMACEUTICALS INC.
Statements of Comprehensive Income
For the years ended December 31
(All amounts expressed in United States dollars)

			2016		2015
Expenses
	General and administrative	$	123,000		131,406
Other Income
	Interest		(112)		(128)
	Foreign exchange loss/(gain)		12,662		(71,128)
Loss for the year		$	(135,550)	$	(60,150)
Other comprehensive (loss)/income			(90,236)		571,382
Comprehensive (loss)/income for the year		$	(225,786)	$	511,232
Loss per share
Basic and diluted		$	(0.007)	$	(0.003)
Weighted average number of shares outstanding			19,659,726		19,659,726

BRADMER PHARMACEUTICALS INC.
Statements of Changes in Shareholders' Equity
For the years ended December 31
(All amounts expressed in United States dollars)

	Share capital
	Number of			Contributed	Accumulated Other Comprehensive					Total Shareholders'
	shares	Amount		surplus	Income/ (Loss)			Deficit		equity
Balance, January 1, 2015	19,659,726	$1,979,314		$ 2,187,203	$	414,186	$	(3,917,801)	$	662,902
Foreign currency translation
adjustment	-	(320,209)		(353,840)		571,382		-		(102,667)
Loss for the year	-	-		-		-		(60,150)		(60,150)
Balance, December 31, 2015	19,659,726	$ 1,659,105	$	1,833,363	$	985,568	$	(3,977,951)	$	500,085
Foreign currency translation
adjustment	-	51,033		56,392		(90,236)		-		17,189
Loss for the year	-	-		-		-		(135,550)		(135,550)
Balance, December 31, 2016	19,659,726	$ 1,710,138	$	1,889,755	$	895,332	$	(4,113,501)	$	381,724

BRADMER PHARMACEUTICALS INC.
Statements of Cash Flows
For the years ended December 31
(All amounts expressed in United States dollars)

				2016		2015
Cash flows from operating activities
	Loss for the year		$	(135,550)	$	(60,150)
	Adjustments for:
		Foreign currency translation adjustment		12,174		(66,063)
				(123,376)		(126,213)
	Change in non-cash operating items
		Amounts receivable		1,685		(4,615)
		Prepaid expenses		92		478
		Accounts payable and accrued expenses		9,720		(11,446)
				(111,879)		(141,796)
Effect of exchange rate fluctuations on cash held				5,015		(36,604)
Decrease in cash				(106,864)		(178,400)
Cash at beginning of year				520,758		699,158
Cash at end of year			$	413,894	$	520,758